OR WAIT 15 SECS
CPhI MEA (Middle East and Africa) launches next month as favorable market conditions are driving increased growth across the Middle East and North Africa (MENA) pharma market and ageing and gentrifying populations, increased healthcare spending, and a modernising supply chain are transforming prospects in the region.
CPhI reports that pharma sales have reached an impressive $32 billion across Middle East and North Africa (MENA) pharma market, with the Middle East accounting for $20.3 billion and North Africa for $10.7 billion. Saudi Arabia remains the biggest pharma market in the region according to 2017 sales numbers at $7.5bn, with Turkey ($6.9bn), Egypt ($3.4bn) and the UAE ($3.17bn) following closely behind. However, overall the North Africa region is predicted to see the fastest growth rates in the next few years at 7.6% CAGR. CPhI Middle East & Africa – organized by UBM (part of Informa Plc) – will launch at the ADNEC centre, Abu Dhabi, for the first time this year (September 3-5, 2018). In a region that relies heavily on imported ingredients and the maintenance of a reliable network of distributors, CPhI MEA is specifically tailored to facilitate new connections between regional and multinational businesses and optimize existing partnerships.
The event will attract key decision makers and budget holders from the region to meet with 4000+ attendees – 50% of which are from outside the MEA region – and 250 local, regional and international exhibitors. The exhibition will feature co-located events, Finished-Dosage-Formulation (FDF), ICSE, P-MEC and InnoPack providing a comprehensive overview of all steps of the supply chain in one location. Representatives from APIs, excipients, IT, analytical services, contract manufacturing, clinical trials, packaging, machinery, and more will be present. For more information or to register to attend the event for free, please visit gotocphi.com/prmea